Ebola: Two vaccines against the Bundibugyo strain to be tested in Bunia starting November 26

Story Africa·18 November 2026·2 min read

Phase 2 trials for two candidate vaccines against the Bundibugyo strain of the Ebola virus are set to begin on November 26 or 27, 2026, in Bunia, the capital of Ituri province in the eastern Democratic Republic of Congo, according to the World Health Organization as cited on November 18, 2026, by Africa Radio and AFP.

Oxford and Moderna in the same protocol

The two candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and mRNA-1469, which stems from the work of the American laboratory Moderna and is based on messenger RNA technology. They were recommended by a group of independent experts convened by the WHO, reports UN News. These are the first candidates specifically targeting the Bundibugyo strain to join the Tumaini clinical trial—meaning "hope" in Swahili—which was launched on October 23 in Bunia and designed to evaluate several vaccines under a single protocol, following a strategy known as ring vaccination around people who have been in contact with confirmed patients. More than 140 people are participating to date, according to the WHO as cited by Africa Radio. UN News specified on November 5 that the integration of the two candidates remained subject to the approval of Congolese health authorities.

Why the existing vaccine is not enough

An Ebola vaccine is already approved: Ervebo, whose efficacy was demonstrated during a trial in Guinea, but against the Zaire species. Its effectiveness against Bundibugyo remains uncertain: the two viruses are related but, according to UN News, present differences that do not allow one to assume that a vaccine protects against both. For this reason, Ervebo is also being evaluated in Tumaini.

An epidemic of unprecedented scale in the country

As of November 1, 2026, the epidemic declared in May had caused 10,532 confirmed cases and 5,126 deaths across eight provinces, according to UN News: nearly one in two recorded patients has died. Ituri is by far the most affected province, with more than 7,400 cases and nearly 3,500 deaths. Cases have also been reported in Kenya and Nigeria. Armed conflicts, difficulties in accessing patients, and mistrust of health authorities are hindering the response.

The Director-General of the WHO, Tedros Adhanom Ghebreyesus, praised "the power of science and partnership," while reminding everyone that vaccines alone would not be enough to end the epidemic. This is also what Congolese frontline healthcare workers were saying at the beginning of the month, as they denounced the delay in funding for the response.

One point remains that deserves to be stated: these trials will take place in Ituri, in the midst of the epidemic, with Congolese teams. The world's first vaccines designed against Bundibugyo will therefore be evaluated by those whom the virus is killing, not after them.

Enjoyed this article? Pass it on.

This article was written in French with the help of artificial intelligence from the sources cited below, then translated from French automatically. Read the original.